Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

New long-term clinical data for Blueprint Medicines' drug Ayvakit (avapritinib) were presented at the ASH congress in Orlando, reinforcing the treatment's pr ...

Sutter Health is the first hospital in the Sacramento Region to offer accelerated TMS therapy for treatment-resistant ...

Music therapy has helped children in the archipelago recover from natural disasters. But the work needs more support.

It can be fairly said that therapy as we know it today is a modern and Western concept. We tend to think of treatment ...

Southwest Research Institute (SwRI) and Trinity University are developing an intranasal (IN) drug-device combination to treat ...

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients ...

Kymera shows strong KT-621 Phase 1b efficacy, solid safety, platform validation, cash runway and growth potential in key ...

Mycosis fungoides, the most prevalent CTCL subtype, accounts for the majority of cases. Although early-stage disease has a five-year survival rate of roughly 88%, it is a chronic cancer with ...

Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results.

America’s labor market started to stall out in the early summer. Between May and August, job gains averaged 31,000 per month, or about one-fifth the monthly rate seen last year. What happened in ...

FORT HOOD, Texas (KWTX) - The Houston based Cobos Law Firm is suing Dr. McGraw on behalf of now 55 former patients of his that say he did everything from filming them without consent to inappropriate ...